Home
Live Updates
Key Takeaways from Phase 4 Switch Trial Presented at AAO : comparemela.com
Key Takeaways from Phase 4 Switch Trial Presented at AAO
Richard Adler, MD, FACS, discusses the Switch trial which compared OTX-101 (cyclosporine ophthalmic solution 0.09%) vs cyclosporine ophthalmic emulsion 0.05% (Restasis) in patients with dry eye disease (DED).
Related Keywords
,
Managing Dry Eye Disease ,
Trial Presented ,
Cequa ,
Open Label ,
Single Arm Study ,
Incomplete Response ,
Restasis ,
Dry Eye Disease ,
Corneal Staining ,
Sande Score ,
Symptom Assessment Questionnaire In Dry Eye Corneal Staining ,
Central Corneal Staining ,
Artificial Tears ,
Fda Trials ,
Total Corneal Clearing ,
Doubling Tear Production ,
Incomplete Response Dry Eye Disease ,
comparemela.com © 2020. All Rights Reserved.